Collaboration Agreement - Additional Information (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended
	May 31, 2021	Feb. 28, 2022	Mar. 31, 2022	Mar. 31, 2021	Jan. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Future milestone payments receivable	$ 135,000
Combined performance obligation			$ 8,300
Development activities performance obligation			3,700
Collaboration revenue			468
Clinical Supply Agreement
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment received	$ 12,000
Upfront payment recognition in future periods to settlement of obligation			$ 12,000
Deferred revenue, description			Under the LianBio License Agreement, in order to evaluate the transaction price for purposes of ASC 606, the Company determined that the upfront payment of $12.0 million and the reimbursable cost of the clinical supply of LYR-210 constitute the entirety of the consideration to be included in the transaction price as of the outset of the arrangement, which was allocated to the two performance obligations as follows: $8.3 million to the Combined Performance Obligation and $3.7 million to the Development Activities Performance Obligation. In February 2022, the Company received $5.0 million upon achievement of the first of the development milestones related to dosing its first patient and the transaction price was adjusted by $5.0 million which was allocated to the two performance obligations as follows: $3.4 million to the Combined Performance Obligation and $1.6 million to the Development Activities Performance Obligation. The remaining potential milestone payments that the Company is eligible to receive were excluded from the transaction price as of March 31 2022, as all milestone amounts were fully constrained based on the probability of achievement.
Revenue related to the achievement of the milestone catch up adjustment			$ 100
Performance Obligations
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue			300	$ 0
Milestone Achievements
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Collaboration revenue		$ 5,000	200	$ 0
Pre-Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment recognition in future periods to settlement of obligation			12,000		$ 12,000
Combined performance obligation			8,259
Development activities performance obligation			3,741
Post-Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment recognition in future periods to settlement of obligation		17,000	17,000
Combined performance obligation			11,700
Development activities performance obligation			5,300
Milestone
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Upfront payment recognition in future periods to settlement of obligation		5,000	5,000
Combined performance obligation		3,400	3,441
Development activities performance obligation		$ 1,600	1,559
Collaboration revenue			$ 5,000